The aim of this project is to promote the reconstruction of haematopoietic function after chemoradiotherapy for cervical cancer with the innovative use of autologous haematopoietic containing stem cell blood transfusion support.To explore the effect of stored hemopoietic stem cell support therapy on bone marrow protection after concurrent chemoradiotherapy, in order to promote its clinical application.
None
None
Parallel
Autologous blood transfusion with haematopoietic stem cells
Other interventionTransfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemoradiotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during chemoradiotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109/L, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109/L.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.
Incidence of Grade 3-4 neutropenia
Incidence of Grade 3-4 neutropenia
Time to reconstruct haematopoietic function
Time to reconstruct haematopoietic function
the rate of postponement of the course of chemoradiotherapy
the rate of postponement of the course of chemoradiotherapy
reduction in chemotherapy dose
reduction in chemotherapy dose
Incidence of febrile neutropenia (FN)
Incidence of febrile neutropenia (FN)
Incidence of hematopoietic stem cell reinfusion treatment Adverse Events [Safety and Tolerability])
Incidence of hematopoietic stem cell reinfusion treatment Adverse Events \[Safety and Tolerability\])
Click on the lead sponsor to view all of their trials.
